Drug · Small Molecule

Sulindac

CI-DRUG-00000563Explore in graph →NCIt C850 CHEMBL15770 CIViC Approved

Regulatory

Approvals (1)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

openfdaRegulatory1 approval record · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
US FDA	—	Carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Sulindac tablets, USP are indicated for acute or long-term use in the relief of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis The safety and effectiveness of sulindac have not been established in rheumatoid arthritis patients who are designated in the American Rheumatism Association classification as Functional Class IV (incapacitated, largely or wholly bedridden, or confined to wheelchair; little or no self-care).	approved	Mar 3, 1988	openfda

Data updated 16 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 3	1	2	22	1	US	Mar 3, 1988	1996-08
Leukemia	Phase2	Phase 2	0	0	1	0	—	—	2014-01
Malignant Breast Neoplasm	Phase2	Phase 2	0	0	2	0	—	—	2002-01
Malignant Colon Neoplasm	Phase2	Phase 2	0	0	1	0	—	—

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PIK3CA Amplification1
Aspirin + Ibuprofen

Clinical trials

Trials with this intervention (22)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–22 of 22 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04207944	The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)	active not recruiting	Phase 2	100	Duke UniversityOTHER	1	Sep 8, 2026	clinicaltrials
NCT01761877	NSAID Effects on Clinical and Imaging Breast Biomarkers	completed	Phase 2	114	Stony Brook University

Molecule

Record

Kind: Small Molecule
Mechanism: Cyclooxygenase inhibitor
Targets: 2 genes
UNII: 184SNS8VUH
Aliases: Aflodac, Algocetil, Apo-Sulin, Arthrocine, Artribid, Cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic Acid, Citireuma, Clinoril, Clisundac, Imbaral, MK-231, Novo-Sundac, NSC-757344, Reumofil, Reumyl, Sudac, Sulindac, Sulindaco, Sulindac Sulfoxide, Sulinol, Sulreuma, (Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic Acid

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (0)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

Data not yet available

No cross-reference code recorded yet beyond the record identifiers above.

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.